Skip to main content
. Author manuscript; available in PMC: 2019 Jul 12.
Published in final edited form as: Dement Geriatr Cogn Disord. 2016 Jan 8;41(1-2):80–92. doi: 10.1159/000441139

Table 3.

Change in diagnosis after receipt of florbetapir scan results

Prescan diagnosis Postscan diagnosis, n (%)
 Change in diagnosis
Due to AD Indeterminate Not due to AD
AUC-like
Amyloid-negative due to AD (n = 7) 0 0 7 (100.0) 7/7 (100.0)
subjects (n = 66) indeterminate (n = 57) 0 30 (52.6) 27 (47.4) 27/57 (47.4)
not due to AD (n = 2) 0 0 2 (100.0) 0/2 (0.0)
Amyloid-positive due to AD (n = 14) 14 (100.0) 0 0 0/14 (0.0)
subjects (n = 59) indeterminate (n = 41) 40 (97.6) 1 (2.4) 0 40/41 (97.6)
not due to AD (n = 4) 4 (100.0) 0 0 4/4 (100.0)
Total 78/125 (62.4)
Non-AUC
Amyloid-negative due to AD (n = 26) 1 (3.8) 22 (84.6) 3 (11.5) 25/26 (96.2)
subjects (n = 50) indeterminate (n = 17) 0 (0.0) 11 (64.7) 6 (35.3) 6/17 (35.3)
not due to AD (n = 7) 0 (0.0) 1 (14.3) 6 (85.7) 1/7 (14.3)
Amyloid-positive due to AD (n = 39) 39 (100.0) 0 (0.0) 0 (0.0) 0/39 (0.0)
subjects (n = 54) indeterminate (n = 7) 7 (100.0) 0 (0.0) 0 (0.0) 7/7 (100.0)
not due to AD (n = 8) 8 (100.0) 0 (0.0) 0 (0.0) 8/8 (100.0)
Total 47/104 (45.2)